Nanotechnology in Drug Delivery Market to Grow at 17.9% CAGR Through 2031, Driven by Rising Targeted Therapy Demand; North America Leads with 40% Share

The Global Nanotechnology in Drug Delivery Market is growing at a CAGR of 17.9 percent during 2024-2031. Nanotechnology-based drug delivery systems include nanoparticles, liposomes, nanocarriers, dendrimers, and polymeric nanomaterials used to enhance drug solubility, bioavailability, targeted delivery, and controlled release for various therapeutic areas. Rising prevalence of chronic diseases, increasing demand for targeted therapies, and the need for improved pharmacokinetics and reduced side effects are driving steady market expansion.

Market growth is further supported by advancements in nanocarrier technologies, increasing investment in R&D, and the growing adoption of personalized medicine. North America holds the largest market share due to strong pharmaceutical infrastructure, high healthcare expenditure, and advanced research capabilities, while Asia Pacific is emerging as a fast-growing region driven by increasing pharmaceutical manufacturing, rising healthcare awareness, and government initiatives supporting nanotechnology adoption.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nanotechnology-in-drug-delivery-market?sai-v

The Nanotechnology in Drug Delivery Market is revolutionizing therapeutics with precision-engineered nanoparticles that enhance targeted delivery, efficacy, and patient outcomes.

Key Developments

United States
✅ November 2025: The U.S. nanotechnology drug delivery market is projected to grow rapidly due to rising prevalence of chronic diseases and increasing demand for targeted therapies.

✅ July 2025: Pharmaceutical and biotech companies deployed advanced nanoparticle-based therapeutics, including liposomes and polymeric nanoparticles, to enhance drug bioavailability, controlled release, and reduce side effects.

✅ April 2025: Nanomedicine adoption expanded in oncology, gene therapy, and mRNA-based treatments as nano-enabled drug delivery helps overcome solubility issues, penetrate the blood-brain barrier, and improve targeting of diseased tissues.

Japan
✅ October 2025: The nanomedicine market in Japan is growing strongly, with drug delivery being the largest contributor to revenue; demand for nano-enabled therapeutics is increasing across multiple disease indications.

✅ July 2025: Japanese pharmaceutical and biotech firms are investing in nanotechnology-based carriers (liposomes, nanoparticles, micelles) for precise and controlled drug delivery, particularly in oncology and chronic disease treatments.

✅ March 2025: A focus on personalized medicine in Japan has driven development of advanced nanocarrier systems to improve therapeutic efficiency, reduce systemic toxicity, and target complex diseases such as cancer and neurological disorders.

Mergers & Strategic Moves

United States
✅ December 2024: A U.S. biotech major acquired a nanomedicine-platform company specializing in nanoparticle formulations to strengthen its pipeline in targeted and RNA-based therapies.

✅ February 2025: An international pharmaceutical firm expanded its nanomedicine capabilities by acquiring a startup focused on lipid-nanoparticle (LNP) platforms - aiming to advance mRNA drug delivery and next-generation therapeutics.

Japan
✅ December 2024: A major Japanese chemical/materials company completed acquisition of a domestic startup specializing in lipid-nanoparticle manufacturing technologies - enabling production of high-quality nanocarriers for drug delivery (e.g., liposomes, nanomedicine).

✅ February 2025: Japanese nanomedicine-materials firms and biotech players increased collaboration via joint development agreements to co-develop next-generation nanoparticle-based drug delivery systems, targeting more effective and stable formulations for both local and global markets.

Key Players
Ceramisphere Health Pvt Limited | Cristal Therapeutics | CYTIMMUNE SCIENCES, Inc. | Nanobiotix | NanoCarrier Co. Ltd. | NanOlogy LLC | EnColl Corporation | EyePoint Pharmaceuticals | AbbVie Inc. | Aquanova AG | BlueWillow Biologics | Camurus AB | Celgene, Inc. | Lena Nanoceutics Ltd.

Key Highlights

• Ceramisphere Health Pvt Limited - Holds 4.3% share of the global nanotechnology drug delivery market, driven by advanced ceramic-based nanoparticle formulations and targeted therapeutic solutions.

• Cristal Therapeutics - Accounts for 3.9% share, supported by polymer-lipid hybrid nanoparticles for oncology and precision medicine applications.

• CYTIMMUNE SCIENCES, Inc. - Represents 2.8% share, specializing in immuno-oncology nanomedicine platforms and enhanced drug delivery systems.

• Nanobiotix - Maintains 5.7% share, recognized for its nanoparticle-enhanced radiotherapy and oncology-focused clinical-stage products.

• NanoCarrier Co. Ltd. - Holds 4.1% share, driven by polymeric micelle drug delivery systems and cancer-targeted therapeutics.

• NanOlogy LLC - Accounts for 2.6% share, known for functionalized nanoparticles for controlled drug release and clinical applications.

• EnColl Corporation - Represents 3.2% share, focused on nanocarriers for biologics and ophthalmic drug delivery platforms.

• EyePoint Pharmaceuticals - Maintains 4.8% share, specialized in ocular drug delivery systems and sustained-release ophthalmic therapies.

• AbbVie Inc. - Holds 9.3% share, leveraging nanotechnology for targeted therapeutics, biologics delivery, and advanced oncology formulations.

• Aquanova AG - Accounts for 2.7% share, recognized for lipid-based nanoparticle formulations enhancing bioavailability and therapeutic efficacy.

• BlueWillow Biologics - Represents 2.9% share, driven by intranasal vaccine delivery systems and nanoscale adjuvant technologies.

• Camurus AB - Maintains 3.5% share, known for advanced lipid-based nanocarriers for controlled and sustained drug release.

• Celgene, Inc. - Holds 5.1% share, leveraging nanomedicine for oncology, immunotherapy, and precision medicine delivery.

• Lena Nanoceutics Ltd. - Accounts for 2.4% share, specialized in nanotechnology platforms for improved bioavailability and targeted therapeutic delivery.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=nanotechnology-in-drug-delivery-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
• Growing demand for targeted and controlled drug delivery systems to improve therapeutic outcomes.

• Rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders.

• Increasing adoption of nanoparticles (liposomes, polymeric nanoparticles, dendrimers, nanocrystals) to enhance drug bioavailability and solubility.

• Advancements in nanotechnology enabling site-specific delivery with reduced side effects.

• Expansion of nanomedicine research funded by government bodies and pharmaceutical companies.

• Rising development of nano-enabled vaccines and gene therapies.
• Growing use of nanocarriers for biologics, peptides, and mRNA-based drugs.

Industry Developments
• Launch of next-generation lipid nanoparticles (LNPs) for mRNA vaccines and nucleic acid therapeutics.

• FDA approvals of nano-formulated cancer drugs, enhancing precision oncology treatment.

• Collaboration between biotech firms and nanotechnology companies for nanoparticle formulation optimization.

• Development of smart nanocarriers capable of stimuli-responsive release (pH, temperature, enzymes).

• Advancements in polymeric nanomaterials improving sustained drug release.

• Increased research into exosome-based nanocarriers for regenerative medicine and drug delivery.

• Partnerships to scale up manufacturing of nanocarriers for vaccines and cell therapies.

Regional Insights
• North America holds 40%, driven by "strong biotechnology and pharmaceutical R&D, government funding for nanomedicine, and rapid adoption of nano-formulated therapeutics."

• Europe accounts for 30%, supported by "expansion of nanotechnology research centers, advancements in cancer nanomedicine, and regulatory backing for novel drug delivery systems."

• Asia-Pacific holds 25%, fueled by "growing healthcare investments, rising cancer burden, and increasing collaborations for nano-enabled drug development."

• Latin America holds 3%, driven by "growing adoption of advanced drug delivery technologies and expansion of pharma manufacturing."

• Middle East & Africa account for 2%, supported by "improving healthcare infrastructure and rising oncology drug demand."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nanotechnology-in-drug-delivery-market?sai-v

Key Segments:

➥ By Technology
Micelles are widely adopted in nanotechnology-based drug delivery due to their excellent solubilization properties, enhanced drug permeability, and capability to encapsulate hydrophobic drugs for targeted release. Nanoparticles remain the dominant technology, enabling precise drug targeting, controlled release, improved bioavailability, and reduced systemic toxicity across multiple therapeutic areas. Liposomes offer biocompatibility, reduced immunogenicity, and effective encapsulation of both hydrophilic and hydrophobic drugs, making them suitable for vaccines, oncology, and chronic disease therapies. Nanocrystals are favored for enhancing the solubility and dissolution rate of poorly water-soluble drugs, supporting faster absorption and higher therapeutic efficacy. Others include dendrimers, carbon nanotubes, polymeric nanoparticles, and nanoemulsions developed for advanced delivery performance, organ-specific targeting, and next-generation drug formulation.

➥ By Application
Anti-infective applications leverage nanotechnology for improved drug penetration, enhanced antimicrobial activity, and the ability to overcome resistance mechanisms for bacterial, viral, and fungal infections. Neurology utilizes nano-enabled carriers for crossing the blood-brain barrier, enabling targeted delivery for neurodegenerative disorders, epilepsy, and CNS infections. Anti-inflammatory/Immunology applications benefit from controlled drug release, improved immune modulation, and reduced side effects in chronic inflammatory and autoimmune conditions. Oncology represents one of the largest segments, using nanocarriers for tumor-targeted delivery, enhanced drug accumulation, reduced toxicity, and improved therapeutic outcomes. Cardiovascular/Physiology applications rely on nanoparticles for targeted delivery to vascular tissues, plaque imaging, controlled drug elution, and regenerative therapies. Others include endocrinology, ophthalmology, dermatology, and rare disease treatments where precision delivery and higher efficacy are essential.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.